Check for Vitamin D deficiency

Vitamin D in Ovarian Cancer Recurrence.

Study Reference: Laboratory / Translational Study 

Ovarian cancer often recurs with poor outcomes, making recurrence prevention a major research focus. Emerging evidence shows that platinum chemotherapy can trigger non-stem cancer cells to convert into chemoresistant stem cells,and relapse. Vitamin D limits this conversion. Chemo treatment exacerbates vitamin D deficiency. Since  20% of Australian women are already vitamin D deficient (a figure rising significantly in winter), routine testing and supplementation offer a safe, accessible strategy to help limit resistance and reduce recurrence risk.

Key Points

  • Driver of Relapse: Platinum chemotherapy may change cancer cells into stem-like cells, causing chemoresistance.

  • Targeted Mechanism: Vitamin D  acts as a brake on this process, helping maintain chemotherapy sensitivity.

  • Common Deficiency: About 1 in 5 Australian women are vitamin D deficient, with higher rates during winter.

  • Exacerbated Deficiency: Cytotoxic chemotherapy regimens can further deplete serum vitamin D levels; this worsens an underlying vulnerability during active treatment.

  • Simple Intervention: Routine screening and corrective supplementation offer a practical, low-risk way to support standard oncology care.

What This Means for Ovarian Cancer Support Nurses

  • Stem Cell Plasticity: Reassure callers that researchers are identifying clear mechanisms behind resistance and actionable ways to counteract them.

  • Seasonal Deficiency: Prompt callers to discuss vitamin D screening with their GP or oncology team, especially during winter.

  • Proactive Care: Encourage callers to manage easily modifiable factors like blood checks and safe supplementation alongside active treatment.

Tags: #OvarianCancer #VitaminD #Chemoresistance #SurvivorshipCare #SupportNursing #IntegrativeOncology

Comments

Post a Comment

Popular posts from this blog

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more

Sugar doesn’t feed cancer

Image
Revisiting the Warburg-Based “Sugar Feeds Cancer” Hypothesis: A Critical Appraisal of Epidemiological, Experimental and Mechanistic Evidence https://tinyurl.com/3v2tysdt Many clinical care professionals receive queries from cancer patients about whether they should modify their diet to red u ce consumed sugar. This concern is based on a misunde r standing of some basic medical research known as the Warbur g effect. Research from 1956 show ed that cancer cells alter their metaboli sm to enable increased glucose uptake and increase energy production. A misunderstanding of this effect has led to incorrect dietary advice to cancer patients suggesting sugar restriction may be benefi cial. As a result, malnutrition , which is already a s i gnificant cause of morbidity for cancer patients , can be exacerbated . No hard evidence that low sugar diets alter survival exists. Some anecdotal reports suggest a slight correlation with risk. This study is a n appraisal of all credible re...
Read more

All about theranostics

Image
Australian ovarian cancer breakthrough enters human trials https://tinyurl.com/ye245f8f Medicine is full of new words or neologisms. Mostly thes e are produced by PR agencies looking for a memorable brand name for a new drug. Sometimes the new name marks a dramatic shift in medical care. One such is theranostic s a complex noun first used in 1997 to name a marriage of therapy and diagnosis. Theranostics are combinations of antibodies and radiopha rmaceuticals currently being used in the treatment o f prostate cancer and carcinoid. The radi o pharmace utical of choice is lutetium-177 which is a n isotope with a short half-life and an intense Beta emitter. Beta radiation is of high energy with low penetration and highly toxic, Standard systemic brachytherapy with Beta emitters is likely to kill the patient before killing the cancer . The antibody combination targets the radiation to the cancer cell meaning only a low non-fatal dose is required . The antibody is produced ...
Read more